A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of BLB-201 Vaccine in Healthy Young Adults and Older Adults
Latest Information Update: 11 Mar 2025
At a glance
- Drugs CPI RSV F vaccine-Blue Lake Biotechnology (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man
- Sponsors Blue Lake Biotechnology
Most Recent Events
- 10 Mar 2025 According to a Blue Lake Biotechnology media release, company announced that it will be presenting safety and immunogenicity data on BLB201 at the 13th International RSV Symposium, occurring March 12-15 in Iguazu, Brazil.
- 25 Oct 2023 According to a Blue lake biotechnology media release, data from this study were published in Science Advances.
- 25 Oct 2023 Results were published in a Blue lake biotechnology Media Release.